Business Description
Spyre Therapeutics Inc
NAICS : 325412
SIC : 2834
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.86 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 21.1 | |||||
3-Year EPS without NRI Growth Rate | 18.6 | |||||
3-Year FCF Growth Rate | 27.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 35.02 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 81.52 | |||||
9-Day RSI | 76.09 | |||||
14-Day RSI | 72.16 | |||||
6-1 Month Momentum % | -21.53 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 19.7 | |||||
Quick Ratio | 19.7 | |||||
Cash Ratio | 19.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -165.9 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -17852.71 | |||||
ROE % | -360.57 | |||||
ROA % | -54.18 | |||||
ROIC % | -388.58 | |||||
3-Year ROIIC % | 467.85 | |||||
ROC (Joel Greenblatt) % | -3840.08 | |||||
ROCE % | -64.41 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 309.18 | |||||
PB Ratio | 9.19 | |||||
Price-to-Tangible-Book | 9.2 | |||||
EV-to-EBIT | -10.88 | |||||
EV-to-EBITDA | -10.88 | |||||
EV-to-Revenue | 2123.07 | |||||
EV-to-FCF | -12.03 | |||||
Price-to-Net-Current-Asset-Value | 9.2 | |||||
Price-to-Net-Cash | 5.52 | |||||
Earnings Yield (Greenblatt) % | -9.19 | |||||
FCF Yield % | -7.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Spyre Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.812 | ||
EPS (TTM) (€) | -12.262 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 72.16 | ||
14-Day ATR (€) | 0.80736 | ||
20-Day SMA (€) | 30.235 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 20.9 - 40.9 | ||
Shares Outstanding (Mil) | 51.43 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Spyre Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Spyre Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Spyre Therapeutics Inc Frequently Asked Questions
What is Spyre Therapeutics Inc(FRA:3920)'s stock price today?
When is next earnings date of Spyre Therapeutics Inc(FRA:3920)?
Does Spyre Therapeutics Inc(FRA:3920) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |